Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at ...

Existing atherosclerotic cardiovascular disease (ASCVD) risk calculators appear to be inadequate, noted researchers led by ...

Current cardiac screening tools used to prevent heart attacks fail to identify nearly half of the people who are actually at ...

Population-based age- and sex-specific percentiles for 30-year cardiovascular disease (CVD) risk have been developed based on ...

Mount Sinai study shows that traditional risk scores and symptoms such as chest pain should not be solely relied upon to ...

Trials of a new cholesterol-lowering pill have shown promising results for people with heterozygous familial ...

PCSK9 inhibitor therapy is less likely to be utilized in Black, Hispanic, and low-income patients hospitalized with ...

Cholesteryl ester transfer protein inhibition has previously demonstrated significant efficacy in reducing atherogenic lipids and may benefit high-risk patients who are unable to achieve their LDL ...

Released in 2023, PREVENT is a tool estimating CVD, ASCVD, and heart failure risk over 10 or 30 years for adults as young as ...

Millions of Americans will board planes and travel long distances this holiday season, many of them living with known heart ...

Statin therapy may attenuate the elevated MACE risk typically observed with tofacitinib vs TNF inhibitors among patients with RA and pre-existing ASCVD.

Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we ...